RayKnowChina Research Map
Shortlist0

Chongqing University

重庆大学

ChongqingUniversity or health system

Hospitals that carry this university's name, added together, plus papers and trials that name only the university.

Research activity, not treatment quality. Not medical advice. How this works

Nasopharyngeal carcinoma

鼻咽癌
0.7%Leads under 1 in 100 of China's research papers on NPC

Led 17 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.4%).

Run this PubMed search

Open trials led
1
Research papers it led
17
Trials it led
5
Share of China's trials
0.8%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 552025
ThemesImaging & AIRadiotherapy techniqueInduction / concurrent chemotherapy

Hospitals counted here

  1. Chongqing University Cancer Hospital14
  2. Chongqing General Hospital3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. A Randomized, Multicenter, Phase 2 Trial of Camrelizumab With or Without Metastasis-directed Stereotactic Body Radiation Therapy in Recurrent or Metastatic Nasopharyngeal Carcinoma.2025International journal of radiation oncology, biology, physicsRCT
  2. Evaluation of the clinical efficacy and safety of Zhuhuang Powder combined with Qingyan Mixture in the prevention and treatment of radiation-induced oral mucositis: A retrospective cohort study.2025MedicineFree full text
  3. A Practical Online Dynamic Nomogram to Predict the Progression-Free Survival in Nasopharyngeal Carcinoma.2025Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery
  4. Prediction of induction chemotherapy response in locoregionally advanced nasopharyngeal carcinoma based on three pretreatment non-Gaussian diffusion MRI models.2025BMC medical imagingFree full text
  5. Evaluation of induction chemotherapy response using multiphasic dual-energy CT in nasopharyngeal carcinoma.2025European radiology
Trials on ClinicalTrials.gov6
  1. Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.RecruitingNCT06059261Lead sponsorPhase 2Start 2026-02
  2. A Study of BL-M08D1 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma and Other Solid TumorsNot yet recruitingNCT07818486Study sitePhase 1/Phase 2Start 2026-09
  3. A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.RecruitingNCT07258979Study sitePhase 1/Phase 2Start 2025-11
  4. Individualized Neck Cervical Irradiation Prophylaxis Trial of NPCRecruitingNCT07303023Study sitePhase 3Start 2025-09
  5. Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment ResponseRecruitingNCT06239727Study sitePhase 3Start 2024-03
  6. A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid TumorsRecruitingNCT05956587Study sitePhase 2Start 2024-01

PubMed searchClinicalTrials.gov

Oesophageal squamous cell carcinoma

食管鳞状细胞癌
0.2%Leads under 1 in 100 of China's research papers on ESCC

Led 6 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.9%).

Run this PubMed search

Open trials led
1
Research papers it led
6
Trials it led
1
Share of China's trials
0.2%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 1120242025: 222025
ThemesImaging & AINeoadjuvant & combined treatmentRadiotherapy

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Chongqing University Cancer Hospital4
  2. Shapingba Hospital, Chongqing University Counted in the group total1
  3. Chongqing University Three Gorges Hospital Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Influence of radiotherapy interruption on esophageal cancer with intensity-modulated radiotherapy: a retrospective study.2024BMC cancerFree full text
  2. Quantitative parameters derived from dual-energy computed tomography for the preoperative prediction of early recurrence in patients with esophageal squamous cell carcinoma.2023European radiology
  3. IL2RB Remodels the Immune Microenvironment and Promotes the Progression of Esophageal Squamous Cell Carcinoma.2025Annals of clinical and laboratory science
  4. Effect of tristetraprolin on esophageal squamous cell carcinoma cell proliferation.2025Tissue & cell
  5. Exosomal PIK3CB promotes PD-L1 expression and malignant transformation in esophageal squamous cell carcinoma.2023Medical oncology (Northwood, London, England)
Trials on ClinicalTrials.gov6
  1. An Observational Study on the Safety and Efficacy of Immunotherapy Combined With Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell CarcinomaRecruitingNCT07080437Lead sponsorStart 2021-03
  2. SKB500 Combinations in Patients With Esophageal Squamous Cell CarcinomaRecruitingNCT07700667Study sitePhase 2Start 2026-08
  3. A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid TumorsTerminatedNCT05427396Study sitePhase 1Start 2022-07
  4. A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)Active, not recruitingNCT05094336Study sitePhase 1/Phase 2Start 2022-02
  5. JMT101 Combined With Afatinib in Patients With Advanced Esophageal Squamous Cell Carcinoma After Standard TherapyStatus unknownNCT05164848Study sitePhase 1Start 2021-12
  6. A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent ChemoradiotherapyCompletedNCT04543617Study sitePhase 3Start 2020-09

PubMed searchClinicalTrials.gov

Hepatocellular carcinoma

肝细胞癌
0.6%Leads under 1 in 100 of China's research papers on HCC

Led 84 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (5.5%).

Run this PubMed search

Open trials led
0
Research papers it led
84
Trials it led
1
Share of China's trials
0.07%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 442025
ThemesImaging, AI & early detectionImmunotherapy & targeted drugsRecurrence & prognosis

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Chongqing University Cancer Hospital23
  2. Chongqing University Jiangjin Hospital11
  3. Chongqing General Hospital Counted in the group total7
  4. Chongqing University Three Gorges Hospital Counted in the group total3
  5. Chongqing University Fuling Hospital Counted in the group total1
  6. Cancer Hospital, Chongqing University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Intermittent Pringle maneuver combined with controlled low Central venous pressure prolongs hepatic hilum occlusion time in patients with hepatocellular carcinoma complicated by post hepatitis B cirrhosis: a randomized c2023Scandinavian journal of gastroenterologyRCT
  2. Targeting PYK2 with heterobifunctional T6BP helps mitigate MASLD and MASH-HCC progression.2025Journal of hepatology
  3. PINK1 dysfunction in hepatocellular carcinoma fosters immune evasion and disease progression by promoting neutrophil infiltration.2025Journal for immunotherapy of cancerFree full text
  4. The Value of Machine Learning-based Radiomics Model Characterized by PET Imaging with 68Ga-FAPI in Assessing Microvascular Invasion of Hepatocellular Carcinoma.2025Academic radiology
  5. Efficacy of radiotherapy combined with hepatic arterial infusion chemotherapy, TKI and ICI for hepatocellular carcinoma with portal vein tumor thrombus: a retrospective cohort study.2025Abdominal radiology (New York)
Trials on ClinicalTrials.gov6
  1. First in Human Study of SIM0610 in Solid TumorsRecruitingNCT07348211Study sitePhase 1Start 2026-01
  2. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 OverexpressionRecruitingNCT07327034Study sitePhase 2Start 2025-06
  3. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid TumorsRecruitingNCT06427941Study sitePhase 1/Phase 2Start 2024-07
  4. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.RecruitingNCT05862337Study sitePhase 3Start 2023-05
  5. Comprehensive Prognostic Model: The Study Introduces a Novel Prognostic Model That Incorporates a Wide Range of Clinical and Laboratory Variables, Providing a More Holistic Approach to Predicting Overall Survival in HCC PatientsCompletedNCT06550739Lead sponsorStart 2019-01
  6. A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular CarcinomaTerminatedNCT05653427Study sitePhase 2Start 2022-12

PubMed searchClinicalTrials.gov

Stomach cancer

胃癌
0.3%Leads under 1 in 100 of China's research papers on Stomach cancer

Led 29 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (3.9%).

Run this PubMed search

Open trials led
0
Research papers it led
29
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 2220242025: 112025
ThemesPeritoneal spread & advanced diseaseSurgeryImaging & AI

Hospitals counted here

  1. Chongqing University Cancer Hospital15
  2. Chongqing University Three Gorges Hospital Counted in the group total4
  3. Chongqing Three Gorges Central Hospital Counted in the group total2
  4. Chongqing University Central Hospital Counted in the group total2
  5. Chongqing Emergency Medical Center1
  6. Three Gorges Hospital, Chongqing University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Magnifying image-enhanced endoscopy-only mode boosted early cancer diagnostic efficiency: a multicenter randomized controlled trial.2023Gastrointestinal endoscopyRCT
  2. Disruption of KDM4C-ALDH1A3 feed-forward loop inhibits stemness, tumorigenesis and chemoresistance of gastric cancer stem cells.2021Signal transduction and targeted therapyFree full text
  3. Robotic vs. laparoscopic gastrectomy for patients with locally advanced gastric cancer: a meta-analysis of randomized controlled trials and propensity-score-matched studies.2025International journal of surgery (London, England)
  4. A Retrospective Observational Study of Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer and Colorectal Cancer From a Single Center in the Recent 5 years.2024Cancer control : journal of the Moffitt Cancer CenterFree full text
  5. Development and validation of a multi-parameter nomogram for venous thromboembolism in gastric cancer patients: a retrospective analysis.2024PeerJFree full text
Trials on ClinicalTrials.gov6
  1. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  2. A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant TumorsRecruitingNCT07070232Study sitePhase 1/Phase 2Start 2025-08
  3. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid TumorsRecruitingNCT06427941Study sitePhase 1/Phase 2Start 2024-07
  4. A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsRecruitingNCT05150691Study sitePhase 1/Phase 2Start 2022-01
  5. A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)Active, not recruitingNCT06356311Study sitePhase 3Start 2024-05
  6. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionCompletedNCT05052801Study sitePhase 3Start 2022-03

PubMed searchClinicalTrials.gov

Hepatoblastoma

肝母细胞瘤
1.3%Leads about 1 in 77 of China's research papers on Hepatoblastoma New since 2021

Led 2 of 154 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (13.6%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 2220212022: 0020222023: 0020232024: 0020242025: 002025

PubMed searchClinicalTrials.gov

Osteosarcoma

骨肉瘤
0.3%Leads under 1 in 100 of China's research papers on Osteosarcoma

Led 7 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
7
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 1120242025: 222025

Over half of these papers are lab or animal studies.

PubMed searchClinicalTrials.gov

Neuroblastoma

神经母细胞瘤
0.2%Leads under 1 in 100 of China's research papers on Neuroblastoma

Led 2 of 1,132 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.8%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.05%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

Hospitals counted here

  1. Chongqing University Cancer Hospital1
  2. Chongqing University Three Gorges Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Multiple myeloma

多发性骨髓瘤
0.3%Leads under 1 in 100 of China's research papers on Myeloma

Led 5 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.8%).

Run this PubMed search

Open trials led
0
Research papers it led
5
Trials it led
2
Share of China's trials
0.4%
Share of the world's papers
0.05%
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 2220242025: 112025
ThemesDiagnosis, MRD & riskStem cell transplantKidney & bone complications

Hospitals counted here

  1. Chongqing University Three Gorges Hospital Counted in the group total2
  2. Chongqing University Cancer Hospital2
  3. Three Gorges Hospital, Chongqing University Counted in the group total1
  4. Fuling Hospital, Chongqing University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Analysis of influencing factors of pulmonary infection during chemotherapy in patients with multiple myeloma and construction of a nomogram prediction model.2025Clinics (Sao Paulo, Brazil)Free full text
  2. Predictive model of the efficiency of hematopoietic stem cell collection in patients with multiple myeloma and lymphoma based on multiple peripheral blood markers.2024International journal of laboratory hematology
  3. XGBoost-based multiparameters from dual-energy computed tomography for the differentiation of multiple myeloma of the spine from vertebral osteolytic metastases.2023European radiology
  4. Identification and prognostic analysis of metabolic genes associated with TP53 mutation in multiple myeloma.2024Hematology (Amsterdam, Netherlands)
  5. miR-26 inhibits proliferation and promotes apoptosis of multiple myeloma cells by targeting BNIP3.2023Cellular and molecular biology (Noisy-le-Grand, France)
Trials on ClinicalTrials.gov6
  1. A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell TumorsRecruitingNCT07179679Study sitePhase 1Start 2025-12
  2. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaRecruitingNCT05552222Study sitePhase 3Start 2022-10
  3. A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple MyelomaRecruitingNCT04973605Study sitePhase 1/Phase 2Start 2021-09
  4. A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other TreatmentsRecruitingNCT05020236Study sitePhase 3Start 2021-10
  5. Clinical Study on PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem CellsStatus unknownNCT06026995Lead sponsorPhase 4Start 2022-03
  6. Efficacy and Safety of PEG-rhG-CSF Injection for Neutrophil Reconstitution Following AHSCT in Lymphoma/Multiple MyelomaStatus unknownNCT06060080Lead sponsorN/AStart 2022-04

PubMed searchClinicalTrials.gov

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症
0.3%Leads under 1 in 100 of China's research papers on Amyotrophic lateral sclerosis ▼ from 0.8%

Led 2 of 779 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.3%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.03%
Papers led per year
2021: 2220212022: 0020222023: 0020232024: 0020242025: 002025

Hospitals counted here

  1. Chongqing University Cancer Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov